A 28-year-old woman with HIV-1 infection (CD4 count 350 cells/μL, viral load 45,000 copies/mL) on a stable regimen of tenofovir + emtricitabine + efavirenz for 6 months presents for routine follow-up. She is planning to conceive in the next 3 months. Her partner is HIV-negative. Which of the following changes to her antiretroviral regimen is most appropriate?

Explanation

## Clinical Context: HIV and Pregnancy Planning The patient is a woman of reproductive age with virologically suppressed HIV (VL 45,000 copies/mL on therapy) planning conception. The critical issue is **teratogenicity of efavirenz in early pregnancy**, which is well-established in the literature. ## Efavirenz and Teratogenicity **High-Yield:** Efavirenz is **contraindicated in women of childbearing potential planning pregnancy** due to: - CNS neural tube defects (NTDs) observed in animal models and some human studies - FDA Pregnancy Category D (evidence of fetal risk; benefits may warrant use in pregnant women despite potential risks) - WHO recommendation: avoid in women of childbearing age unless no alternatives available **Key Point:** The risk of NTDs with efavirenz exposure in the first trimester is approximately 0.5–1.4 per 1000 live births (higher than baseline population risk of ~1 per 1000). ## Preferred Agents in Pregnancy | Drug Class | Agent | Safety in Pregnancy | Notes | |------------|-------|-------------------|-------| | NRTI | Tenofovir | Preferred | Minimal fetal toxicity; widely used | | NRTI | Emtricitabine | Preferred | Extensive pregnancy experience | | NNRTI | Efavirenz | **Avoid** | Teratogenic; NTD risk | | NNRTI | Rilpivirine | Avoid | Insufficient pregnancy data | | PI | Lopinavir/ritonavir | Acceptable | Preferred PI in pregnancy; hyperglycemia risk | | **INSTI** | **Dolutegravir** | **Preferred** | Excellent efficacy, minimal teratogenicity; integrase inhibitors are first-line in pregnancy | | INSTI | Bictegravir | Preferred | Alternative INSTI | ## Recommended Regimen for Pregnancy **Clinical Pearl:** Current WHO and DHHS guidelines recommend: - **Integrase inhibitor (dolutegravir or bictegravir) + tenofovir + emtricitabine** as the preferred regimen for women planning pregnancy or already pregnant. - Dolutegravir has the strongest evidence base for safety and efficacy in pregnancy. **The correct answer is to switch efavirenz to dolutegravir**, maintaining the backbone of tenofovir + emtricitabine, which are safe in pregnancy. ## Why Other Options Are Incorrect **Warning:** Continuing efavirenz exposes the fetus to a known teratogen during organogenesis (weeks 3–8), when neural tube closure occurs. Lopinavir/ritonavir, while acceptable in pregnancy, is not preferred over integrase inhibitors due to: - Higher rates of hyperglycemia and lipid abnormalities - Inferior virological suppression compared to dolutegravir - Greater pill burden [cite:WHO Consolidated Guidelines on HIV, Sexual and Reproductive Health 2023; DHHS Perinatal HIV Guidelines 2023]